SCHOTT Pharma KGaA (1SXP) Stock Overview
Develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
Rewards
Risk Analysis
No risks detected for 1SXP from our risk checks.
1SXP Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
SCHOTT Pharma AG & Co. KGaA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €13.56 |
| 52 Week High | €30.25 |
| 52 Week Low | €13.26 |
| Beta | 0.92 |
| 1 Month Change | -9.48% |
| 3 Month Change | -9.60% |
| 1 Year Change | -43.26% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -56.68% |
Recent News & Updates
Recent updates
SCHOTT Pharma AG & Co. KGaA Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Feb 14
There Is A Reason SCHOTT Pharma AG & Co. KGaA's (ETR:1SXP) Price Is Undemanding
Feb 02SCHOTT Pharma KGaA (ETR:1SXP) Will Pay A Larger Dividend Than Last Year At €0.18
Dec 15A Look At The Fair Value Of SCHOTT Pharma AG & Co. KGaA (ETR:1SXP)
Nov 24Is SCHOTT Pharma KGaA (ETR:1SXP) Using Too Much Debt?
Nov 02Investor Optimism Abounds SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) But Growth Is Lacking
Sep 19Analysts Are Updating Their SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Estimates After Its Third-Quarter Results
Aug 15These 4 Measures Indicate That SCHOTT Pharma KGaA (ETR:1SXP) Is Using Debt Reasonably Well
Jul 19Does SCHOTT Pharma KGaA (ETR:1SXP) Deserve A Spot On Your Watchlist?
Jun 13Earnings Beat: SCHOTT Pharma AG & Co. KGaA Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
May 18An Intrinsic Calculation For SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Suggests It's 40% Undervalued
Apr 27We Think SCHOTT Pharma KGaA (ETR:1SXP) Can Stay On Top Of Its Debt
Mar 22SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Investors Are Less Pessimistic Than Expected
Feb 12Is SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Trading At A 49% Discount?
Jan 13
Global Expansion And Innovative Pharma Solutions Set To Boost Revenue And Profitability
SCHOTT Pharma's global expansion and innovative product offerings are expected to drive revenue growth and improve profitability by meeting market demand and increasing efficiencies.These 4 Measures Indicate That SCHOTT Pharma KGaA (ETR:1SXP) Is Using Debt Reasonably Well
Nov 25SCHOTT Pharma AG & Co. KGaA's (ETR:1SXP) Business Is Trailing The Market But Its Shares Aren't
Oct 27SCHOTT Pharma AG & Co. KGaA Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Sep 01Is There An Opportunity With SCHOTT Pharma AG & Co. KGaA's (ETR:1SXP) 31% Undervaluation?
Aug 07Earnings Miss: SCHOTT Pharma AG & Co. KGaA Missed EPS By 18% And Analysts Are Revising Their Forecasts
Jul 01We Think SCHOTT Pharma KGaA (ETR:1SXP) Can Stay On Top Of Its Debt
Jun 07Calculating The Intrinsic Value Of SCHOTT Pharma AG & Co. KGaA (ETR:1SXP)
Mar 28Shareholder Returns
| 1SXP | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -3.0% | -4.6% | -0.6% |
| 1Y | -43.3% | -26.2% | -1.8% |
Return vs Industry: 1SXP underperformed the German Life Sciences industry which returned -26.2% over the past year.
Return vs Market: 1SXP underperformed the German Market which returned -1.8% over the past year.
Price Volatility
| 1SXP volatility | |
|---|---|
| 1SXP Average Weekly Movement | 4.4% |
| Life Sciences Industry Average Movement | 7.9% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in DE Market | 14.4% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 1SXP has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 1SXP's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1884 | 4,829 | Andreas Reisse | www.schott-pharma.com |
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; SCHOTT TOPPAC unique, a polymer container; and SCHOTT TOPPAC cartridge. It also provides pharmaceutical glass cartridge, such as cartriQ for peptide and protein-based injectables; cartriQ Large Volume for large-volume injectables; Cartridges Double Chamber for lyophilized drugs; Cartridges Break Resistant; and TopLine and StandardLine cartridges and vials.
SCHOTT Pharma AG & Co. KGaA Fundamentals Summary
| 1SXP fundamental statistics | |
|---|---|
| Market cap | €2.04b |
| Earnings (TTM) | €149.95m |
| Revenue (TTM) | €995.03m |
Is 1SXP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1SXP income statement (TTM) | |
|---|---|
| Revenue | €995.03m |
| Cost of Revenue | €660.29m |
| Gross Profit | €334.74m |
| Other Expenses | €184.80m |
| Earnings | €149.95m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 13, 2026
| Earnings per share (EPS) | 1.00 |
| Gross Margin | 33.64% |
| Net Profit Margin | 15.07% |
| Debt/Equity Ratio | 28.8% |
How did 1SXP perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/15 10:09 |
| End of Day Share Price | 2026/03/13 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SCHOTT Pharma AG & Co. KGaA is covered by 20 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gaurav Jain | Barclays |
| Pallav Mittal | Barclays |
| Christian Ehmann | Berenberg |